Cystic fibrosis microbiology: Advances in antimicrobial therapy

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Valerie Waters, Alan Smyth

Abstract

Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently been introduced (such as inhaled aztreonam), and others are in development (inhaled levofloxacin and liposomal amikacin). Licensed dry powder formulations include tobramycin inhalation powder and dry powder colistimethate (available in Europe). Although inhaled antibiotics have the advantage of being able to deliver high intrapulmonary concentrations of drug, antimicrobial resistance can still develop and is a concern in CF. Antimicrobial resistance might be mitigated by using non-antibiotic treatments, antibiotic adjuvants, which have activity against bacteria. Examples include agents such as gallium, antimicrobial peptides and anti-biofilm compounds such as alginate oligosaccharides (OligoG) and garlic. Vaccination strategies and antibody therapy (IgY) against Pseudomonas aeruginosa have also been attempted to prevent initial infection with this organism in CF. Although aggressive and long-term use of antibiotics has been crucial in slowing lung function decline and improving survival in people with CF, it has added a significant burden of ca...Continue Reading

References

Mar 1, 1992·Pediatric Pulmonology·R L HenryL Petrovic
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·W M ShaferR I Lehrer
Oct 4, 2002·The New England Journal of Medicine·Alice S Prince
Nov 1, 2002·The Lancet Infectious Diseases·Miguel CámaraAndrea Hardman
Sep 2, 2003·Nature Reviews. Immunology·Tomas Ganz
Nov 25, 2003·Nature·Thien-Fah MahGeorge A O'Toole
Feb 18, 2005·Journal of Bacteriology·Thomas Bovbjerg RasmussenMichael Givskov
Apr 29, 2005·Pediatric Pulmonology·Charles R EstherMargaret W Leigh
Aug 27, 2005·Nature·Lucas R HoffmanSamuel I Miller
Nov 17, 2006·Journal of Medical Microbiology·J R W Govan
Jan 20, 2007·American Journal of Respiratory and Critical Care Medicine·Nicole Mayer-HamblettBonnie W Ramsey
Mar 14, 2007·Pediatric Pulmonology·David E GellerCarol Conrad
Mar 17, 2007·The Journal of Clinical Investigation·Yukihiro KanekoPradeep K Singh
Jun 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Gerd DöringUNKNOWN Flagella Vaccine Trial Study Group
Aug 19, 2007·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Denis HadjiliadisShaf Keshavjee
Feb 12, 2008·American Journal of Respiratory and Critical Care Medicine·Michael M TunneyJ Stuart Elborn
Jul 29, 2008·American Journal of Respiratory and Critical Care Medicine·Karen S McCoyA Bruce Montgomery
Aug 6, 2008·Pediatric Pulmonology·Elin NilssonHans Kollberg
Oct 28, 2008·Patient Education and Counseling·Gary LatchfordMark Conner
May 19, 2009·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Paul S McNamaraKevin W Southern
Oct 20, 2009·The Journal of Thoracic and Cardiovascular Surgery·Mark J RussoJoshua R Sonett
Jun 3, 2010·Antimicrobial Agents and Chemotherapy·Karin BodewitsDominic J Campopiano
Jun 17, 2010·JAMA : the Journal of the American Medical Association·Elliott C DasenbrookMichael P Boyle
Oct 5, 2010·American Journal of Respiratory and Critical Care Medicine·Valerie WatersFelix Ratjen
Oct 22, 2010·Pediatric Pulmonology·Samuel M MoskowitzJane L Burns
Nov 16, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael W KonstanDavid E Geller
Jan 22, 2011·BMC Pulmonary Medicine·Becky A BriesacherLynne M Quittell

❮ Previous
Next ❯

Citations

Feb 10, 2016·Clinics in Chest Medicine·Jaideep S Talwalkar, Thomas S Murray
Dec 22, 2015·International Journal of Medical Microbiology : IJMM·Maitrayee ChatterjeeRaja Biswas
Sep 12, 2015·Jornal de pediatria·Jose Dirceu Ribeiro, Gilberto Bueno Fischer
Jul 28, 2016·Pediatric Allergy, Immunology, and Pulmonology·Hengameh H RaissyH William Kelly
May 4, 2016·Lancet·J Stuart Elborn
Apr 8, 2016·The Lancet. Respiratory Medicine·Kris De Boeck, Margarida D Amaral
Jul 30, 2016·Pediatric Clinics of North America·Edith T Zemanick, Lucas R Hoffman
Jan 28, 2017·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Piera ValentiFrancesca Berlutti
Dec 7, 2016·Expert Review of Anti-infective Therapy·G PoulakouG Dimopoulos
Nov 9, 2016·Scientific Reports·Yajie WangBernd H A Rehm
Mar 10, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Marjan M HashemiPaul B Savage
Sep 20, 2018·Human Vaccines & Immunotherapeutics·Aymn Talat AbbasEsam Ibraheem Ahmed Azhar
Jul 10, 2018·The Journal of Antimicrobial Chemotherapy·Laura MüllerSabine Wronski
Oct 10, 2018·Antimicrobial Agents and Chemotherapy·Mathias MüskenSusanne Häussler
Oct 13, 2016·ERJ Open Research·Patricia Moran LosadaBurkhard Tümmler
Sep 8, 2019·World Journal of Microbiology & Biotechnology·Hamed MemarianiAbdolmajid Ghasemian
Jan 5, 2020·Applied Microbiology and Biotechnology·Wankuson ChanasitBernd H A Rehm
Nov 3, 2015·Current Opinion in Infectious Diseases·Katherine M LanganAnton Y Peleg
Aug 4, 2020·Expert Opinion on Investigational Drugs·Ranjani SomayajiScott C Bell
May 27, 2020·The Pediatric Infectious Disease Journal·Roberto Rosales-ReyesJosé Ignacio Santos-Preciado
Jun 17, 2020·Antimicrobial Agents and Chemotherapy·Devin SindeldeckerPaul Stoodley
Jul 26, 2017·Drugs·Garyphallia PoulakouGeorge Dimopoulos
Feb 23, 2018·American Journal of Respiratory Cell and Molecular Biology·Jens KlockgetherBurkhard Tümmler
Jul 22, 2020·Drugs·Matteo BassettiMaddalena Peghin
Sep 1, 2017·FEMS Microbiology Letters·Wynne D SmithJane C Davies
Oct 21, 2020·Expert Opinion on Therapeutic Patents·Annalisa BiancheraRuggero Bettini
Jun 21, 2021·Biochimica Et Biophysica Acta. General Subjects·Martin van EijkHenk P Haagsman
Oct 21, 2021·Molecular Ecology Resources·Bravada M HillAmanda M V Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Related Papers

Paediatric Drugs
Mireille van Westreenen, Harm A W M Tiddens
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
G McCaugheyMichael M Tunney
Expert Review of Respiratory Medicine
Stanley B Fiel
American Journal of Respiratory and Critical Care Medicine
David E GellerMpex 204 Study Group
© 2022 Meta ULC. All rights reserved